$1.68
0.00% today
Nasdaq, Nov 13, 03:48 pm CET
ISIN
IL0010852080
Symbol
CGEN

Compugen Ltd. Stock price

$1.68
-0.56 25.00% 1M
+0.36 27.27% 6M
+0.15 9.80% YTD
+0.08 5.00% 1Y
+0.85 101.27% 3Y
-11.59 87.34% 5Y
-4.97 74.74% 10Y
-1.07 38.91% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-0.04 2.33%
ISIN
IL0010852080
Symbol
CGEN
Industry

Key metrics

Basic
Market capitalization
$157.1m
Enterprise Value
$63.3m
Net debt
positive
Cash
$93.9m
Shares outstanding
94.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.1 | 23.9
EV/Sales
2.9 | 9.6
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
47.8%
Return on Equity
-25.5%
ROCE
-23.0%
ROIC
-7,827.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$22.1m | $6.6m
EBITDA
$-19.3m | -
EBIT
$-19.8m | $-36.1m
Net Income
$-19.4m | $-32.3m
Free Cash Flow
$-9.3m
Growth (TTM | estimate)
Revenue
-48.2% | -76.4%
EBITDA
-374.7% | -
EBIT
-335.8% | -140.9%
Net Income
-103.1% | -130.6%
Free Cash Flow
-141.4%
Margin (TTM | estimate)
Gross
62.3%
EBITDA
-87.3% | -
EBIT
-89.5%
Net
-87.4% | -490.5%
Free Cash Flow
-42.0%
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
1.1%
Employees
74
Rev per Employee
$380.0k
Show more

Is Compugen Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Compugen Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Compugen Ltd. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Compugen Ltd. forecast:

Buy
90%
Hold
10%

Financial data from Compugen Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
22 22
48% 48%
100%
- Direct Costs 8.35 8.35
48% 48%
38%
14 14
63% 63%
62%
- Selling and Administrative Expenses 9.99 9.99
2% 2%
45%
- Research and Development Expense 24 24
26% 26%
107%
-19 -19
375% 375%
-87%
- Depreciation and Amortization 0.49 0.49
2% 2%
2%
EBIT (Operating Income) EBIT -20 -20
336% 336%
-89%
Net Profit -19 -19
103% 103%
-87%

In millions USD.

Don't miss a Thing! We will send you all news about Compugen Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Compugen Ltd. Stock News

Neutral
Seeking Alpha
3 days ago
Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director David Silberman - Chief Financial Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Daina Graybos...
Neutral
PRNewsWire
3 days ago
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel and France in the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in patients with platinum sensitive ovarian cancer with interim analysis now estimated in Q1 2027 SITC 2025 – Co...
Neutral
PRNewsWire
9 days ago
HOLON, Israel , Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2025 Healthcare Conference in New York City.
More Compugen Ltd. News

Company Profile

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Head office Israel
CEO Anat Cohen-Dayag
Employees 74
Founded 1993
Website cgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today